Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
COSMO Pharmaceuticals N.V. ( (CH:COPN) ) has issued an update.
Cosmo Pharmaceuticals N.V. announced its participation in upcoming healthcare investor conferences in London and Windsor, where key executives will engage with investors through presentations and one-on-one meetings. These events are part of Cosmo’s strategy to strengthen investor relations and showcase its leadership in AI-driven healthcare and specialty pharmaceuticals.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF77.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a life-science company specializing in MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). Founded in 1997 and headquartered in Dublin, Ireland, the company designs and manufactures advanced medical solutions trusted by global pharma and MedTech companies, aiming to empower patients and medical professionals through innovative technologies.
Average Trading Volume: 19,915
Technical Sentiment Signal: Buy
Current Market Cap: CHF1.14B
See more data about COPN stock on TipRanks’ Stock Analysis page.